Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Non-Current Liabilities (2016 - 2025)

Seres Therapeutics' Total Non-Current Liabilities history spans 11 years, with the latest figure at $97.8 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 36.12% year-over-year to $97.8 million; the TTM value through Sep 2025 reached $97.8 million, down 36.12%, while the annual FY2024 figure was $124.2 million, 69.09% down from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $97.8 million at Seres Therapeutics, down from $108.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $408.8 million in Q2 2024 and bottomed at $97.8 million in Q3 2025.
  • The 5-year median for Total Non-Current Liabilities is $235.0 million (2022), against an average of $247.5 million.
  • The largest annual shift saw Total Non-Current Liabilities surged 58.86% in 2022 before it tumbled 73.36% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $211.9 million in 2021, then surged by 58.86% to $336.6 million in 2022, then grew by 19.39% to $401.8 million in 2023, then plummeted by 69.09% to $124.2 million in 2024, then dropped by 21.28% to $97.8 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Total Non-Current Liabilities are $97.8 million (Q3 2025), $108.9 million (Q2 2025), and $111.8 million (Q1 2025).